Esperion Therapeutics, Inc.

Total Valuation

Esperion Therapeutics, Inc. carries a market capitalization of 661.15M, placing it among publicly traded companies globally. Its enterprise value stands at 703.60M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Esperion Therapeutics, Inc. currently has 257.40M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 1.45, and the price-to-book ratio stands at -0.37.

Enterprise Valuation

On an enterprise value basis, Esperion Therapeutics, Inc. trades at an EV/EBITDA multiple of 9.27 and an EV/FCF ratio of 10.51. The EV/Sales ratio of 1.68 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 9.28 provides insight into valuation relative to core operating earnings.

Financial Position

Esperion Therapeutics, Inc. maintains a current ratio of 1.53, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -82.04, indicating conservative leverage, while an interest coverage ratio of 0.89 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Stock Price Statistics

Esperion Therapeutics, Inc.'s stock has gained approximately 160.65574% over the past 52 weeks. The 50-day moving average sits at 3.15, while the 200-day moving average is 3.09.

Income Statement

Over the trailing twelve months, Esperion Therapeutics, Inc. generated 418.24M in revenue and converted that into -7.42M in net income, yielding earnings per share of -0.03. EBITDA reached 75.89M, while operating income came in at 75.79M.

Balance Sheet

Esperion Therapeutics, Inc. holds 156.16M in cash and equivalents against 252.63M in total debt, resulting in a net debt position of 93.91M. Total book value stands at -1.65B, with working capital of 159.10M providing operational flexibility.

Cash Flow

Esperion Therapeutics, Inc. produced -18.19M in operating cash flow over the past twelve months. After subtracting -189,000.00 in capital expenditures, free cash flow totaled -18.38M - equivalent to -0.08 per share.

Margins

Esperion Therapeutics, Inc. operates with a gross margin of 68.38, reflecting its pricing power and cost economics. The operating margin of 18.12 and net profit margin of -1.77 provide insight into operational efficiency.

Dividends & Yields

Scores

Esperion Therapeutics, Inc. posts an Altman Z-Score of -2.66, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.